Stockreport

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update 

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
PDF Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company a [Read more]